HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Givaudan sales and earnings

This article was originally published in The Rose Sheet

Executive Summary

Swiss fragrance firm booked $2.34 bil. in sales for FY 2006, it announces Feb. 20. Both fragrance and flavor divisions of the company achieved above market sales growth despite continued ingredients streamlining, which impacted annual sales by $26.6 mil. The fragrance division recorded sales of $984.8 mil., a rise of 8.2% from FY 2005, driven by double-digit growth in fine fragrances and strong performances from consumer products and specialty ingredients. Givaudan attributes expansion of its market position in FY 2006 to new sales and growth strategies; the firm acquired Quest International in November for $2.3 bil. (1"The Rose Sheet" Nov. 27, 2006, In Brief)...

Latest Headlines
See All
UsernamePublicRestriction

Register

RS014555

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel